Huntsville, ALNCT07037433Now EnrollingIRB Ready

Heart Disease Clinical Trial in Huntsville, AL

Access cutting-edge heart disease treatment through this phase 3 clinical trial at a research site in Huntsville. Study-provided care at no cost to qualified participants.

Sponsored by Amgen

Quick Self-Assessment

See if you qualify for this Huntsville location

Preparing your pre-screening questions…

Expert Care in Huntsville

Access heart disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related heart disease treatment provided free

Apply for This Huntsville Location

Check if you qualify for this heart disease clinical trial in Huntsville, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Huntsville

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Huntsville site if eligible
  4. 4Begin participation

About This Heart Disease Study in Huntsville

The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

Sponsor: Amgen

Who Can Participate

Inclusion Criteria

Age ≥ 45 years at screening.
BMI of ≥ 27.0 kg/m\^2 at screening.
History of Atherosclerotic Cardiovascular Disease (ASCVD) with a documented history of at least one of the following:
Prior MI (presumed atherothrombotic event due to plaque rupture/erosion).
Prior ischemic stroke (presumed due to atherosclerosis; may include ischemic stroke with hemorrhagic transformation).
Symptomatic peripheral arterial disease (PAD), as evidenced by intermittent claudication with ankle-brachial index (ABI) \< 0.9 (at rest), or peripheral arterial revascularization procedure, or amputation due to atherosclerotic disease.

Exclusion Criteria

History of any of the following within 60 days before screening or between screening and randomization: MI, hospitalization for unstable angina, arterial revascularization (eg, coronary, cerebrovascular or peripheral) major cardiovascular surgery, stroke, or transient ischemic attack (TIA).
New York Heart Association (NYHA) class IV HF during screening or hospitalization for HF within 60 days before screening or between screening and randomization.
Type 1 DM, or any other type of diabetes with the exception of T2DM or prior gestational diabetes. Participants with a history of gestational diabetes should be stratified according to their current diabetes classification.
For participants with T2DM (including those without a prior history of T2DM but with a HbA1c ≥ 6.5% during screening):
HbA1c \> 10.0% (86 mmol/mol) at screening.
History of diabetic ketoacidosis or hyperosmolar state/coma within 12 months before randomization.
One or more episodes of severe hypoglycemia within 6 months before randomization and/or history of hypoglycemia unawareness.
History of proliferative diabetic retinopathy, diabetic maculopathy, severe non-proliferative diabetic retinopathy, or currently receiving or planning to receive treatment for diabetic retinopathy and/or diabetic macular edema.
Use of any glucagon-like peptide-1 receptor agonist (GLP-1 RA), glucose-dependent insulinotropic polypeptide (GIP) agonists or antagonists, or amylin analogs within 90 days before randomization or planned use during the conduct of the trial.
History of chronic pancreatitis or history of acute pancreatitis in the 180 days before screening or between screening and randomization.
Family (first-degree relative\[s\]), or personal history of medullary thyroid carcinoma (MTC), or multiple endocrine neoplasia syndrome type 2 (MEN-2).
Calcitonin ≥ 50 ng/L (pg/mL) at screening.
Acute or chronic hepatitis; signs and symptoms of any liver disease other than metabolic dysfunction-associated steatotic liver disease, or alanine aminotransferase (ALT) \> 3.0 x the upper limit of normal (ULN) during screening, or total bilirubin (TBL) \> 1.8 x ULN during screening (for participants with a known diagnosis of Gilbert syndrome, direct bilirubin should be used instead of TBL).
History of malignancy within the last 5 years before screening or between screening and randomization (except for the following treated with curative intent: non-melanoma skin cancer, breast ductal carcinoma in situ, cervical carcinoma in situ, or prostate cancer in situ).
Participants of childbearing potential planning to become pregnant while on study or unwilling to use protocol-specified methods of contraception during treatment.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Huntsville?

Yes, this clinical trial (NCT07037433) has an active research site in Huntsville, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Heart Disease Treatment Options in Huntsville, AL

If you're searching for heart disease treatment options in Huntsville, AL, this clinical trial (NCT07037433) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Huntsville research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced heart disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all heart disease clinical trials near you to find additional studies recruiting in your area.

More Heart Disease Trials in Huntsville, AL

See all heart disease clinical trials recruiting in Huntsville — not just this study.

Browse Heart Disease Trials in Huntsville →

Browse More Trials by Condition

Heart Disease TrialsValvular Heart Disease TrialsMyocarditis TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Huntsville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Huntsville, AL